GIMBE: Eventi, progetti, pubblicazioni e altre attività istituzionali della Fondazione GIMBE
Metodologiche: articoli pertinenti le aree del know-how GIMBE, pubblicati nei top-six journals*
Cliniche: articoli di ricerca clinica primaria e secondaria pubblicati nei top-six journals*
Sanità: notizie dalla sanità italiana
Eventi: congressi, conferenze, workshop nazionali e internazionali relativi alle aree del know-how GIMBE
*N Engl J Med, Lancet, Ann Intern Med, JAMA, BMJ, PLos Med
16 marzo 2019Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: systematic review and meta-analysis of randomised controlled trials
Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study
True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study
14 marzo 2019A Randomized Trial of Prophylactic Antibiotics for Miscarriage Surgery
N Engl J Med 2019;380:1012-1021
N Engl J Med 2019;380:1012-1021
ChiudiSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
N Engl J Med 2019;380:1022-1032
N Engl J Med 2019;380:1022-1032
Chiudi 12 marzo 2019Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model
PLoS Med 2019;16(3): e1002758.
PLoS Med 2019;16(3): e1002758.
Chiudi 9 marzo 2019Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study
Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank
Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial
Lancet 2019;393:1009-1020
Lancet 2019;393:1009-1020
ChiudiEfficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
Lancet 2019;393:1021-1032
Lancet 2019;393:1021-1032
Chiudi